Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 413.98M | 429.63M | 408.55M | 333.95M | 265.99M |
Gross Profit | 270.05M | 278.72M | 140.37M | 101.66M | 76.44M |
EBITDA | 73.94M | 87.80M | 87.01M | 66.13M | 50.77M |
Net Income | 15.60M | 31.31M | 31.26M | 18.73M | 9.97M |
Balance Sheet | |||||
Total Assets | 484.66M | 450.97M | 420.86M | 403.40M | 356.29M |
Cash, Cash Equivalents and Short-Term Investments | 54.89M | 65.60M | 76.00M | 84.29M | 73.32M |
Total Debt | 226.46M | 205.26M | 166.38M | 173.20M | 180.77M |
Total Liabilities | 386.83M | 346.17M | 326.13M | 320.02M | 289.65M |
Stockholders Equity | 94.47M | 102.85M | 92.97M | 81.77M | 64.78M |
Cash Flow | |||||
Free Cash Flow | 43.61M | 27.63M | 53.03M | 70.18M | 51.91M |
Operating Cash Flow | 52.65M | 51.13M | 63.04M | 80.69M | 57.88M |
Investing Cash Flow | -17.04M | -27.46M | -20.83M | -10.36M | -19.94M |
Financing Cash Flow | -46.91M | -34.16M | -51.23M | -60.49M | 4.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $16.45B | 10.04 | -7.22% | 3.35% | 1.53% | -21.72% | |
59 Neutral | €358.63M | 22.97 | 15.82% | 3.53% | -3.64% | -50.51% | |
― | €81.46M | ― | -33.85% | 2.64% | ― | ― | |
― | €9.89M | 3.99 | 42.99% | ― | ― | ― | |
― | €86.65M | 5.68 | 10.47% | 2.36% | ― | ― | |
79 Outperform | €153.99M | 20.75 | 2.36% | 8.59% | -22.37% | ||
67 Neutral | €23.78M | 37.80 | ― | 6.63% | 292.55% |
Roche Bobois SA reported its 2024 annual results, showing resilience despite a challenging market environment. The company saw a slight revenue decline of 3.6% to 414 million euros, with EBITDA aligning with expectations at 74.4 million euros. The company maintained strong financial health with significant cash flows and plans to propose a dividend of 1.25 euros per share. Strategic investments in expanding owned stores in key regions like the US and China are expected to support future growth, with a positive outlook for 2025 revenue and EBITDA.